Study of a new drug for platinum-resistant ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests a new investigational drug called JSKN003 for people with ovarian cancer that has stopped responding to standard chemotherapy. The goal is to see if this drug can help shrink tumors and slow down the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years of age or older.
- You must have ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that has been confirmed by a biopsy.
- Your cancer must have stopped responding to platinum-based chemotherapy (like carboplatin or cisplatin) or come back within 6 months after treatment.
- You must have at least one tumor that can be measured on a scan (like a CT or MRI).
- You must be in fairly good physical shape (able to do light activities and care for yourself), and your doctor expects you to live at least 3 more months.
- You cannot have had certain other cancer treatments, other cancers in the past 5 years, or serious lung or other health conditions that might interfere with this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called SHR-A1921 for people with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if it can shrink tumors or slow the cancer's growth.
This trial tests a new drug, HS-20089, for people with ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This study tests a new combination treatment for people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has progressed after at least two prior treatments. The aim is to see if this treatment can help shrink tumors and improve outcomes.
This trial tests an investigational drug called TORL-1-23 for people with ovarian cancer that has stopped responding to platinum chemotherapy. It aims to see if the drug can help shrink or control the cancer.
This study tests a new oral drug called NMS-03305293 for women with recurrent ovarian cancer. It may work by targeting a specific protein involved in cancer growth. You may be eligible if you have high-grade serous ovarian cancer, have had limited prior treatments, and do not have a BRCA mutation.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.